pdufa.bio

RINVOQ (upadacitinib)

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

RINVOQ (upadacitinib) The FDA approved it on Oct 13, 2025. 1 FDA decision on record below. Every date links its source.

ABBV catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Oct 13, 2025 ✓ ApprovedABBV

Questions

When is RINVOQ (upadacitinib)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for RINVOQ (upadacitinib); 1 FDA decision is on record below.

What happened at RINVOQ (upadacitinib)'s most recent FDA decision?

On Oct 13, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has RINVOQ (upadacitinib) been approved by the FDA?

Yes. The FDA approved an application for RINVOQ (upadacitinib) on Oct 13, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.